MNOVHealthcare · BiotechnologyMNOV Stock Forecast: MediciNova, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering MediciNova, Inc. hold a median 12-month price target of $10 — +651.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 12 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
MNOV stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores MediciNova, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (90): The share price has been relatively steady.
Growth (49): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
MNOV stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MNOV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +651.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 May 2026 | D. Boral Capital | Maintains | Buy | $9.00 |
| 23 Mar 2026 | Maxim Group | Reinstates | Buy | $6.00 |
| 16 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 30 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 18 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 31 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 22 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 24 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 June 2025 | B. Riley Securities | Maintains | Buy | — |
| 9 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 2 Dec 2024 | D. Boral Capital | Initiates | Buy | — |
| 10 Mar 2021 | Maxim Group | Initiates | Buy | — |
| 13 Mar 2020 | B. Riley FBR | Maintains | Buy | — |
| 13 Mar 2020 | B. Riley Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MNOV appears on the weeks it earns a place.
MNOV analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
MediciNova, Inc. (MNOV) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −5.5×
- Price / sales
- 108.9×
- Price / book
- 1.6×
- EV / EBITDA
- −2.9×
Cheaper than 90% of US stocks
Cheaper than 4% of US stocks
Cheaper than 53% of US stocks
Cheaper than 74% of US stocks
- Revenue growth (YoY)
- 23.2%
- Earnings growth (YoY)
- —
- Gross margin
- 9.0%
- Operating margin
- −1516.6%
- Net margin
- 7.6%
Higher than 74% of US stocks
Higher than 9% of US stocks
Higher than 5% of US stocks
Higher than 65% of US stocks
- Return on equity
- −26.2%
- Return on assets
- −17.0%
- Dividend yield
- —
Higher than 28% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MNOV vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MediciNova, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about MNOV stock
What is the MNOV stock price forecast for 2026-2027?
The 3 Wall Street analysts covering MediciNova, Inc. have a median 12-month price target of $10, with estimates ranging from $6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MNOV stock a buy right now?
Of the 3 analysts covering MediciNova, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MediciNova, Inc. 89 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MNOV?
As at 12 Aug 2026, MediciNova, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (90 of 100).
Will MNOV stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +651.9% from the last close, and Ticker Nerd's factor model ranks MediciNova, Inc. 89 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MNOV stock forecast for 2030?
No analyst covering MediciNova, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MNOV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $11 over the next 12 months.
How has MNOV stock performed over the past year?
MediciNova, Inc. returned +2.3% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does MediciNova, Inc. do?
MediciNova Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for unmet medical needs.
About MediciNova, Inc.
MediciNova Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for unmet medical needs. The company's primary mission is to improve patient outcomes through innovative treatments that address diverse and challenging conditions, particularly those in the fields of neurology, respiratory, and liver diseases. MediciNova's pipeline includes several investigational drugs targeting neurological disorders such as multiple sclerosis and amyotrophic lateral sclerosis (ALS), as well as potential treatments for respiratory ailments and non-alcoholic steatohepatitis (NASH). Headquartered in California, MediciNova plays a significant role in advancing medical research and development. Its work contributes to critical sectors of the healthcare industry by aiming to bring new solutions to the market that address areas with few existing treatment options. As a participant in the global biopharmaceutical landscape, MediciNova collaborates with research institutions and industry partners, enhancing its ability to innovate and fulfill its commitment to improving lives through science.
CEO Dr. Yuichi Iwaki M.D., Ph.D. · 6 employees · United States · https://medicinova.com